Results 31 to 40 of about 5,503 (166)

Phosphoglycerate dehydrogenase positively regulates the proliferation of chicken muscle cells

Poultry Science, 2022
: Phosphoglycerate dehydrogenase (PHGDH) is the rate-limiting enzyme in the serine synthesis pathway. However, the regulatory role of PHGDH in muscle development is unclear.
Han Wang, Moran Hu, Zhaoxue Ding, Xiaolong Zhou, Songbai Yang, Zhonghao Shen, Feifei Yan, Ayong Zhao   +7 more
doaj   +1 more source

Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma

BMC Medical Genomics, 2023
Background PHGDH (Phosphoglycerate Dehydrogenase) is the first branch enzyme in the serine biosynthetic pathway and plays a vital role in several cancers. However, little is known about the clinical significance of PHGDH in endometrial cancer.
He Zhang, Weimin Kong, Xiaoling Zhao, Yunkai Xie, Dan Luo, Shuning Chen   +5 more
doaj   +1 more source

PHGDH as a mechanism for resistance in metabolically-driven cancers

Cancer Drug Resistance, 2020
At the forefront of cancer research is the rapidly evolving understanding of metabolic reprogramming within cancer cells. The expeditious adaptation to metabolic inhibition allows cells to evolve and acquire resistance to targeted treatments, which makes therapeutic exploitation complex but achievable.
Rathore, Richa, Schutt, Charles R., Van Tine, Brian A.   +2 more
openaire   +3 more sources

Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis

Cell Reports, 2020
Summary: Phosphoglycerate dehydrogenase (PHGDH) is the first enzyme in the serine synthesis pathway in which it is also the rate-limiting enzyme. It is significantly upregulated in many cancers, especially breast cancer.
Chao Wang, Xingyou Wan, Tong Yu, Zhenyu Huang, Chao Shen, Qian Qi, Sheng Xiang, Xinyuan Chen, Eyal Arbely, Zhi-Qiang Ling, Chen-Ying Liu, Wei Yu   +11 more
doaj   +1 more source

Targeting phosphoglycerate dehydrogenase in multiple myeloma

Experimental Hematology & Oncology, 2021
Background Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are required.
Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slørdahl, Torstein Baade Rø, Eline Menu, Anne-Marit Sponaas, Magne Børset   +9 more
doaj   +1 more source

PHGDH Is Upregulated at Translational Level and Implicated in Platin-Resistant in Ovarian Cancer Cells

Frontiers in Oncology, 2021
BackgroundPlatinum-based chemotherapy is the first line option for ovarian cancer. The development of resistance to such chemotherapy results in treatment failure, while the underlying mechanisms are poorly understood.MethodsClinical samples were ...
Fangfang Bi, Yuanyuan An, Tianshui Sun, Yue You, Qing Yang   +4 more
doaj   +1 more source

ZEB1 Transcriptionally Activates PHGDH to Facilitate Carcinogenesis and Progression of HCC

Cellular and Molecular Gastroenterology and Hepatology, 2023
Phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the de novo serine synthesis pathway (SSP), has been implicated in the carcinogenesis and metastasis of hepatocellular carcinoma (HCC) because of its excessive expression and promotion of SSP.
Huihui Wang, Furong Lin, Zhenzhen Xu, Shengnan Yu, Guannan Li, Shan Liao, Wentao Zhao, Fengqiong Zhang, Jinyang Wang, Shijie Wang, Cong Ouyang, Cixiong Zhang, Hailong Xia, Yufei Wu, Bin Jiang, Qinxi Li   +15 more
openaire   +3 more sources

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer

Translational Oncology, 2016
Tumors have exceptionally high demands for energy and anabolism because of their rapid growth. The de novo serine synthesis pathway initiated by phosphoglycerate dehydrogenase (PHGDH) has been recognized as a hallmark of metabolic adaption in ...
Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang, Xiaoyu Zhou, Jiahai Shi   +7 more
doaj   +1 more source

Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?

Cell Death Discovery, 2021
To sustain their malignancy, tumour cells acquire several metabolic adaptations such as increased oxygen, glucose, glutamine, and lipids uptake. Other metabolic processes are also enhanced as part of tumour metabolic reprogramming, for example, increased
Megan Jessica McNamee, David Michod, Maria Victoria Niklison-Chirou   +2 more
doaj   +1 more source

Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer

Oncotarget, 2016
3-Phosphoglycerate dehydrogenase (PHGDH) has recently been identified as an attractive target in cancer therapy as it links upregulated glycolytic flux to increased biomass production in cancer cells. PHGDH catalyses the first step in the serine synthesis pathway and thus diverts glycolytic flux into serine synthesis.
Unterlass JE, Baslé A, Blackburn TJ, Tucker J, Turlais F, Cano C, Noble MME, Curtin NJ   +7 more
openaire   +3 more sources